Psyence Group (TSE:PSYG) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Psyence Group’s NASDAQ-listed associate, Psyence Biomedical, has announced the recruitment of Empax Center in Australia as the second site for its Phase IIb clinical trial on psilocybin-based treatments for Adjustment Disorder in palliative care. This marks a significant milestone as the trial aims to begin patient treatments soon with the first subject expected in early December. The company looks forward to announcing topline data by the second half of 2025, which could lead to pivotal registrational studies.
For further insights into TSE:PSYG stock, check out TipRanks’ Stock Analysis page.
